Survival advantage opens personalized route for Apogenix's glioblastoma therapy
This article was originally published in Scrip
Apogenix's glioblastoma treatment APG101 can increase overall survival in patients positive for a biomarker associated with the drug's target, new analyses of its Phase II study have shown. The data make it the first product in many years to prolong life in this notoriously difficult to treat disease, and encourage the company to hope that it may become the new standard of care in this disease.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.